The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
Ozempic was first approved by the FDA in 2017 for blood sugar control in Type 2 diabetes. It received a cardiovascular indication in 2020 and is now the most broadly indicated GLP-1 receptor agonist ...
The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Singer Avery has been diagnosed with a condition that's thought to affect over 10 million Americans after she began using ...
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback